drugset / Trial / NCT00498056
Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa
Phase 2
Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID)
Centers for Disease Control and Prevention · collabHIV Vaccine Trials Network · collabInternational AIDS Vaccine Initiative · collabUS Military HIV Research Program · collabVaccine Research Center · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The development of a safe and effective vaccine is the best strategy for preventing the spread of HIV-1. The purpose of this study is to determine the safety and effectiveness of and immune responses to an HIV vaccine regimen in healthy adults at risk for HIV infection.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Publications
- Background Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med. 2003 May;3(3):183-93. doi: 10.2174/1566524033479825.
- Background Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science. 2002 Jun 28;296(5577):2354-60. doi: 10.1126/science.1070441.
- Background Johnston MI, Fauci AS. An HIV vaccine--evolving concepts. N Engl J Med. 2007 May 17;356(20):2073-81. doi: 10.1056/NEJMra066267. No abstract available.
- Background Stratov I, DeRose R, Purcell DF, Kent SJ. Vaccines and vaccine strategies against HIV. Curr Drug Targets. 2004 Jan;5(1):71-88. doi: 10.2174/1389450043490686.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VRC-HIVADV014-00-VP | Vaccine | — | Intramuscular |
| Subject | VRC-HIVDNA016-00-VP | Vaccine | — | Intramuscular |